Retatrutide and Fatty Liver Disease (MASLD/MASH)

The Phase 2 Liver Fat Sub-Study

Study design

• 98 participants with MASLD and at least 10% liver fat (measured by MRI-PDFF)
• 48-week trial, randomized to retatrutide 1mg, 4mg, 8mg, 12mg, or placebo
• Primary endpoint: relative change in liver fat at 24 weeks
• Liver fat was measured using MRI-proton density fat fraction (MRI-PDFF), the gold standard non-invasive measurement

Liver fat reduction at 24 weeks

All active doses achieved statistically significant liver fat reduction compared to placebo. The effect was strongly dose-dependent, with the 8mg and 12mg doses producing the most dramatic results.

Key findings

• Liver fat normalization: At the 12mg dose, 86% of participants achieved liver fat below 5% — the threshold for normal. The study did not use liver biopsies to establish MASH resolution or fibrosis improvement.
• Dose response: The 8mg and 12mg groups had similar mean liver-fat reductions. This small substudy does not establish an optimal treatment dose for MASLD.
• Correlation with metabolic improvements: Liver fat reductions correlated with weight loss, reductions in abdominal fat, and improved insulin sensitivity.
• Placebo showed no change: The placebo group had a 0.3% increase in liver fat over the same period, underscoring that these reductions were drug-driven.

Why Retatrutide May Be Uniquely Effective for Liver Fat

Glucagon receptor activation provides a plausible additional liver mechanism. However, the human substudy found that liver-fat reductions correlated with weight loss and did not isolate how much benefit came from each receptor. The proposed mechanisms below should be read as biological explanations under investigation, not proven separate effects in patients.

Glucagon's direct liver effects

• Increased hepatic fatty acid oxidation — glucagon signals the liver to burn fat for energy rather than store it
• Decreased lipogenesis — glucagon reduces the liver's production of new fat
• Increased energy expenditure — glucagon promotes thermogenesis, shifting the body's overall energy balance

Why this matters for MASLD

How Retatrutide Compares to Other Treatments

Retatrutide's MRI findings should not be ranked against biopsy results from trials of other drugs. The study populations, endpoints, and follow-up differ.

• Retatrutide: investigational; the Phase 2a substudy measured liver fat by MRI at 24 and 48 weeks.
• Resmetirom (Rezdiffra): an approved treatment for selected adults with MASH and liver fibrosis.
• Semaglutide (Wegovy): FDA-approved for MASH with moderate-to-advanced fibrosis; its evidence includes biopsy endpoints.

A clinician needs to establish whether someone has steatosis alone, MASH, and/or significant fibrosis before discussing treatment. An MRI liver-fat percentage does not by itself answer all of those questions.

The Phase 3 MASLD Master Protocol

• Registry ID: NCT07165028
• Design: Phase 3 master protocol studying multiple agents in MASLD; retatrutide is one of the agents included (see also SYNERGY-OUTCOMES)
• Enrollment: ~4,500 participants (estimated)
• Status: Recruiting
• Context: Builds on the completed Phase 2 MASLD sub-study (above); this is separate from TRIUMPH-5, which is the head-to-head obesity trial vs tirzepatide (NCT06662383)

If Phase 3 data confirm the Phase 2 liver-fat findings in a formal outcomes setting, retatrutide could support a MASLD/MASH label expansion in addition to obesity. Effective, well-tolerated treatments for fatty liver disease remain a major unmet medical need.

Understanding MASLD and MASH

What is MASLD?

MASLD (metabolic dysfunction-associated steatotic liver disease) is the accumulation of excess fat in the liver in the presence of at least one metabolic risk factor (obesity, type 2 diabetes, dyslipidemia, or hypertension). It is the most common chronic liver disease worldwide, affecting approximately 38% of the global adult population.

What is MASH?

MASH (metabolic dysfunction-associated steatohepatitis) is the more severe form of MASLD where liver fat accumulation is accompanied by inflammation and liver cell damage. MASH can progress to:

• Fibrosis — scarring of the liver
• Cirrhosis — advanced, irreversible scarring that impairs liver function
• Hepatocellular carcinoma — liver cancer
• Liver failure — requiring transplantation

Why current treatment options are limited

Until recently, the primary treatment for MASLD/MASH was lifestyle modification — weight loss through diet and exercise. While effective, sustained weight loss is difficult for most patients. Resmetirom (Rezdiffra) was approved in 2024, and semaglutide (Wegovy) received a MASH indication in 2025 for selected adults with moderate-to-advanced fibrosis. Retatrutide's strong liver fat data has generated interest as a potential option that addresses both obesity and liver fat simultaneously.

Frequently Asked Questions

Sources

• Sanyal, A.J., et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. DOI: 10.1038/s41591-024-03018-2
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Younossi, Z.M., et al. (2023). The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology.
• ClinicalTrials.gov: NCT04881760